Document is current

Article History

Received: 24 May 2024

Accepted: 22 November 2024

First Online: 4 December 2024

Declarations

:

: BSB holds stock options for CB Therapeutics. He has also served on advisory boards for CB Therapeutics, Compass Pathways, Janssen Pharmaceuticals, and Livanova. He receives monetary compensation for editorial work for DynaMed Plus (EBSCO Industries, Inc). He has received research funding from Compass Pathways, MindMed, and Reunion Neuroscience. Within the last two years he has consulted for Cerebral. MSD is an employee of Allucent. FK holds stock in Compass Pathways and Cybin. He also serves on the scientific advisory board for Apex Labs. He has consulted for Cybin in the last two years and has received monetary compensation from Vital for teaching. He has received research support from Tryp Therapeutics. EEM has received research support from Tryp Therapeutics. AC is a retired Assistant Special Agent in Charge of the Drug Enforcement Administration who, as an element of that position, had supervisory oversight of the local DEA Diversion Control Program which has Federal regulatory responsibility over Schedule I researchers. AC is a paid regulatory consultant for Mind Medicine, Inc, Multidisciplinary Association of Psychedelic Studies, and the Arizona Criminal Justice Commission. AC has also performed paid regulatory consultancies for Usona Institute, Pacific Neurological Institute Foundation, Fungi Perfecti, Freedom Biosciences, Journey Clinical, and a paid Subject Matter Expert for the US Health and Human Services, Substance Abuse and Mental Health Services Administration. Support for SMN through the Johns Hopkins Center for Psychedelic and Consciousness Research was provided by Tim Ferriss, Matt Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra Cohen Foundation. SMN was also co-investigator on a psilocybin clinical trial funded by Usona Institute. PSH is on the scientific advisory board of Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, Journey Colab Corporation, and Reset Pharmaceuticals Inc. GRG is the President of the Heffter Research Institute. The other authors declare no conflicts of interest.